EEDGAR/calls
The BriefMarketsAll StocksNewsScreenerCommunity

Get the Brief in your inbox

A daily, SEC-grounded read on the market — movers, earnings, and our boldest calls. Free.

EEDGAR/calls

SEC-grounded equity research — opinionated calls reasoned over real filings.

Research

  • The Brief
  • Markets
  • All Stocks
  • Screener
  • Discover
  • Research
  • The Flip Side
  • Track record

Tools

  • Compare
  • Congress trades
  • Events
  • Filing search
  • Groups
  • Trending
  • News

More

  • Pricing
  • Community
  • Newsletter
  • Developers / API
  • Account
DisclosuresTermsPrivacy

Research & education only — not financial advice. EDGAR is not a registered investment adviser; calls are impersonal, generated from SEC filings and a delayed/third-party price feed, and may be wrong or out of date. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates — see Disclosures. Do your own research.

EDGAR® is a registered trademark of the U.S. Securities and Exchange Commission. EDGAR/calls is not affiliated with, endorsed by, or approved by the U.S. Securities and Exchange Commission.

EEDGAR/calls
The BriefMarketsAll StocksNewsScreenerCommunity

Pulling SEC filings + quote and writing the call…

EEDGAR/calls
The BriefMarketsAll StocksNewsScreenerCommunity
← New search
Home›Stocks›PLRZ

PLRZ

Polyrizon Ltd.

Hold
$13.80
▲ +8.24%
$13.80▲ +226.24%
over 1Y
L $3.13EODHDH $17.17
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today+8.2%
1W+20.8%
1M-2.1%
3M+14.2%
YTD+8.2%
1Y+226.2%
OverviewFinancialsValuationQualityFilings
Rating
Hold
Quality
C-
Valuation
Undervalued
Hold
Conviction
Horizon
Medium (3–12mo)

Undemanding valuation (P/E 2.8).

Return on equity -15.9% · latest

The read

Middling fundamentals offset by an attractive price (~172% below fair value) — worth a look on the value angle.

Polyrizon Ltd. shows limited reported revenue, and -15.9% ROE.

Supporting the case: undemanding valuation (P/E 2.8).

Financials · annual, by fiscal year

Line itemFY22FY23FY24FY25
Revenue————
Gross profit————
Operating income-$895K-$635K-$1.30M-$6.25M
Net income-$779K-$600K-$1.54M-$3.33M
Diluted EPS$0.60$494.40$805.20$4.90
Net margin————

Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.

Key statistics

Valuation

Enterprise value$27.5M
EV / EBITDA—
EV / Sales—
EV / FCF—
P / FCF—
PEG (trailing)—
Earnings yield-11.6%
FCF yield-15.8%

Quality & risk

ROIC (est.)-23.5%
Free cash flow-$4.54M
Total debt—
Net cash$1.31M
Piotroski F-Score3/6

Capital returns

Buyback yield—
Dividend yield (est.)—
Shareholder yield—
Shares Δ YoY-61.7%

Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.

Recent filings

all on EDGAR ↗
6-KPeriod ending 2026-07-022026-07-02open ↗6-KPeriod ending 2026-06-292026-06-29open ↗6-KPeriod ending 2026-06-172026-06-17open ↗6-KPeriod ending 2026-06-152026-06-15open ↗6-KPeriod ending 2026-06-102026-06-10open ↗6-KPeriod ending 2026-06-082026-06-08open ↗6-KPeriod ending 2026-06-082026-06-08open ↗6-KPeriod ending 2026-06-052026-06-05open ↗6-KPeriod ending 2026-05-272026-05-27open ↗6-KPeriod ending 2026-05-132026-05-13open ↗EFFECTFiling2026-05-04open ↗6-KPeriod ending 2026-05-042026-05-04open ↗

Quality score

C-
ValueGrowthProfitHealthMom.
ValueA+
GrowthF
ProfitabilityF
Financial healthC
MomentumA-
  • ✗Profitable (positive net income)
  • ✗Return on equity above 15%
  • ✓P/E below 25

Fair value est.

$37.49

Undervalued +172% vs price

cheapfair valueexpensive

Modified Graham: EPS $4.90 × (8.5 + 1.5 × 0.0% growth) × 0.90 quality = 7.7× multiple. An estimate, not a price target.

3.1352-week17.17
Revenue
—
Net margin
—
ROE
-15.9%
P/E
2.8

SEC fundamentals · FY 2025

■ revenue · ■ net income, by fiscal year

Net income-$3.33M-115.9%
Operating income-$6.25M-380.0%
Diluted EPS$4.90-99.4%
Cash & equivalents$1.31M-48.9%
Total assets$21.4M+286.5%
Stockholders' equity$21.0M+297.2%

Frequently asked

Is Polyrizon Ltd. (PLRZ) a buy?
PLRZ currently carries a Hold rating with 3/5 conviction, derived from its latest SEC filings. Undemanding valuation (P/E 2.8).
What is PLRZ's fair value?
A Modified-Graham model based on PLRZ's SEC fundamentals estimates a fair value of about $37.49. It is an estimate from reported earnings, not a price target.
Is PLRZ overvalued or undervalued?
Against a Modified-Graham fair-value estimate, PLRZ currently appears undervalued relative to its SEC-grounded earnings power.
What is Polyrizon Ltd.'s quality score?
PLRZ scores 52.06463590422634/100 (grade C-) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.

Sources: SEC EDGAR (CIK 0001893645, latest 6-K filed 2026-07-02) · EODHD · as of 7/3/2026, 7:44:00 PM.

Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.

Insider activity

Form 4 · SEC
2026-03-31
Izraeli Tomer
Chief Executive Officer
Sell500.00 @ $11.85$5.92K
2026-03-31
Carmel Liron
Director
Sell942.00 @ $12.36$11.6K
2026-03-31
Adler Oz
Director
Sell3.29K @ $12.05$39.7K
2026-03-30
Carmel Liron
Director
Sell100.00 @ $11.00$1.10K
2026-03-30
Izraeli Tomer
Chief Executive Officer
Sell3.90K @ $10.90$42.5K
2026-03-30
Turgeman Tidhar
Chief Technology Officer
Sell2.92K @ $10.90$31.8K

Recent news

market news →
Top Biotech Gainers: QURE Rallies On AMT-130 Update, LNAI On Track, FTH Eyes Q4 Data, ELTX On WatchBullish
nasdaq.com· 2026-06-18
Top Biotech Gainers: AKTX Rallies; GOVX Up On Ebola Concerns; SLGL Awaits Catalysts; CMMB On WatchBullish
nasdaq.com· 2026-05-26
Polyrizon Intends to Acquire up to 20% Stake in Colugo, Developer of Advanced eVTOL Drones for Defense and Urban Air Mobility ApplicationsBullish
globenewswire.com· 2026-03-24
Weekly Roundup on the Cannabis Sector & Psychedelic SectorBullish
finance.yahoo.com· 2026-02-08
Polyrizon Announces New Pre-Clinical Results: PL-14 Demonstrates Significant Allergen-Blocking Performance Compared to a Standard ComparatorBullish
globenewswire.com· 2026-01-05
As Flu Surge Continues, Polyrizon's Nasal Spray Emerges as Potential Extra Shield Solution for Both Vaccinated and UnvaccinatedBullish
globenewswire.com· 2026-01-02

Vs tracked universe

compare →

1196 tracked peers · median

EDGAR Score52 vs 67
Revenue growth— vs 7.5%
Net margin— vs 10.0%
Return on equity-15.9% vs 12.0%
P/E2.8 vs 26.2

News sentiment

EODHD · 2d
Bullish
+0.17
vs typical · 2 articles
↑ improving

Recent news tone vs the market's typical (which skews positive). A soft signal, not a recommendation.